RxDoctor Payments Data

Tu Anh Khuu, MD

Internal Medicine · N Charleston, SCNPI 1154616837

Payments from drug & device makers

$6,529in general payments, 2019–2025

Across 360 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • AstraZeneca$787
  • Novo Nordisk$704
  • Bayer$472
  • Boehringer Ingelheim$378
  • Pfizer$343
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,529100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,529 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$108,029
Medicare patients
213
Services billed
1,229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide117$213,313
OzempicSemaglutide100$213,124
EliquisApixaban66$63,705
TrulicityDulaglutide26$47,155
FarxigaDapagliflozin Propanediol27$36,553
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$36,362
RybelsusSemaglutide25$35,020
JardianceEmpagliflozin24$31,203
JanuviaSitagliptin Phosphate25$29,863
Synjardy XrEmpagliflozin/Metformin Hcl29$28,283
EntrestoSacubitril/Valsartan11$21,463
LinzessLinaclotide15$20,809
MyrbetriqMirabegron13$16,373
Soliqua 100-33Insulin Glargine/Lixisenatide11$11,908
Repatha SyringeEvolocumab13$10,918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,076$260,467143 claims
Novo NordiskOzempic, Rybelsus$704$248,143125 claims
PfizerEliquis$343$63,70566 claims
Boehringer IngelheimJardiance, Synjardy Xr$378$59,48653 claims
AstraZenecaFarxiga, Symbicort$787$41,61640 claims
MerckJanuvia, Janumet Xr$29$39,96836 claims
GSKTrelegy Ellipta$211$36,36223 claims
AbbVieLinzess, Synthroid$299$21,83837 claims
NovartisEntresto$109$21,46311 claims
Astellas Pharma US IncMyrbetriq$44$16,37313 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$148$11,90811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in N Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →